HXN-2006 / Earendil Labs - LARVOL DELTA

A bispecific TROP2/PDL1 antibody-drug conjugate demonstrates enhanced antitumor activity and favorable safety profile (AACR 2026) - "The bsAb TOP1i conjugated ADC (α TROP2/PDL1-TOP1i) exhibited enhanced potency, characterized by robust cytotoxicity against multiple Trop2/PDL1-expressing cell lines, potent bystander killing effects, and tumor regression in multiple CDX models. Notably, the ADC showed excellent stability and tolerability in cynomolgus monkeys, with no significant adverse effects observed in safety studies.Conclusionα TROP2/PDL1-TOP1i represents a promising therapeutic strategy for treatment-resistant cancers, effectively combining PD1/PDL1 immune checkpoint blockade with TROP2-targeted cytotoxic payload delivery while maintaining a favorable safety profile, supporting its advancement to clinical development."

ADC • Bispecific • Clinical • Oncology • TACSTD2 • TOP1